Amneal receives approval for generic version of ortho evra®

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced that it has received abbreviated new drug application (anda) approval from the u.s. food and drug administration (fda) for 150 mcg/day norelgestromin and 35 mcg/day ethinyl estradiol transdermal system. in conjunction with its approval, amneal received a competitive generic therapy (cgt) designation by the fda and has been granted 180 days of exclusivity. amneal's norelgestr
AMRX Ratings Summary
AMRX Quant Ranking